You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Muscle Invasive Urothelial Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nivolumab in Japanese Muscle-invasive Urothelial Carcinoma

Not yet recruiting
  • Muscle-invasive Urothelial Carcinoma
    • City, State, Japan
      Local Institution
    Mar 20, 2023

    Preferences for Japanese Muscle-invasive Urothelial Carcinoma of

    Not yet recruiting
    • Urinary Bladder Neoplasms
      • (no location specified)
      Feb 14, 2023

      Protocol for Muscle Invasive Urothelial Carcinoma of Urinary

      Recruiting
      • Bladder Cancer
      • terta modal bladder preservation
      • Assiut, Assuit, Egypt
        Assuit university
      Aug 13, 2022

      Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma Trial in New York (BGJ398)

      Active, not recruiting
      • Bladder Cancer
      • Non-Muscle-Invasive Urothelial Carcinoma
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Feb 3, 2022

      Urothelial Carcinoma, Bladder Cancer Trial in United States (drug, radiation, biological)

      Recruiting
      • Urothelial Carcinoma
      • Bladder Cancer
      • Durvalumab (Cohort 1-3)
      • +7 more
      • Phoenix, Arizona
      • +10 more
      Jan 11, 2023

      Muscle-invasive Urothelial Carcinoma of the Bladder Trial in Milan (Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA])

      Not yet recruiting
      • Muscle-invasive Urothelial Carcinoma of the Bladder
      • Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
      • Milan, MI, Italy
        Fondazione San Raffaele
      Sep 8, 2022

      High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications Trial

      Recruiting
      • High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
      • +2 more
      • hyperthermic intravesical perfusion
      • Zhengzhou, Henan, China
        BR-PRG
      Sep 15, 2022

      Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

      Active, not recruiting
      • Muscle Invasive Bladder Cancer
      • Urothelial Carcinoma
      • Tianjin, Tianjin, China
        Tianjin Medical University Second Hospital
      Nov 23, 2022

      Muscle-invasive Bladder Cancer Trial in Canada (Whole-body FDG PET-CT)

      Active, not recruiting
      • Muscle-invasive Bladder Cancer
      • Whole-body FDG PET-CT
      • Hamilton, Ontario, Canada
      • +5 more
      Apr 19, 2022

      Infiltrating Bladder Urothelial Carcinoma Trial in France (Durvalumab, Tremelimumab, MVAC Protocol)

      Recruiting
      • Infiltrating Bladder Urothelial Carcinoma
      • Paris, Ile De France, France
      • +14 more
      Apr 21, 2022

      Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

      Not yet recruiting
      • Urothelial Carcinoma Bladder
      • Androgen Receptor Positive
      • Providence, Rhode Island
        Lifespan Cancer Institute
      May 1, 2023

      Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma Trial in Tampa (Adoptive Cell Therapy with Tumor-infiltrating

      Recruiting
      • Urothelial Carcinoma
      • Non-Invasive Bladder Urothelial Carcinoma
      • Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
      • Tampa, Florida
        Moffitt Cancer Center
      Mar 2, 2023

      Urothelial Carcinoma of the Urinary Bladder Trial in New York (Cabazitaxel, Gemcitabine, Cisplatin)

      Recruiting
      • Urothelial Carcinoma of the Urinary Bladder
      • New York, New York
        Columbia University Medical Center- HIP
      Feb 3, 2022

      Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder

      Not yet recruiting
      • Non-muscle-invasive Bladder Cancer
      • +2 more
      • PDD-TURBT with hexaminolevulinate (Hexvix®)
      • Power Led Saphira (TM) from KARL STORZ
      • (no location specified)
      Jul 24, 2023

      Urothelial Carcinoma Trial in France, Italy, United States (retifanlimab, epacadostat, INCAGN02385)

      Recruiting
      • Urothelial Carcinoma
      • Iowa City, Iowa
      • +11 more
      Dec 1, 2022

      Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,

      Recruiting
      • Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
      • Disitamab Vedotin Tislelizumab
      • Disitamab Vedotin
      • Tianjin, Tianjin, China
        Tianjin Medical University Second Hospital
      Aug 9, 2022

      Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab

      Not yet recruiting
      • Localized Muscle Invasive Bladder Urothelial Carcinoma
      • Muscle-Invasive Bladder Carcinoma
      • Sacituzumab govitecan
      • Adaptive Radiotherapy
      • Cleveland, Ohio
        Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
      Apr 18, 2023

      Neutrophils to Lymphocytes Ratio in Predicting Response to BCG

      Completed
      • Urinary Bladder Cancer
      • +4 more
      • Neutrophil to lymphocyte ratio
      • Cairo, Egypt
        Ain Shams university
      Jul 15, 2023

      High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab Nab paclitaxel)

      Recruiting
      • High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
      • Tislelizumab Nab paclitaxel
      • Tianjin, Tianjin, China
        Tianjin Medical University Second Hospital
      Jun 9, 2022

      Bladder Cancer Trial in Houston (Bladder tumor biopsy)

      Recruiting
      • Bladder Cancer
      • Bladder tumor biopsy
      • Houston, Texas
        Baylor College of Medicine
      Jan 14, 2022

      Bladder Cancer, Urothelial Carcinoma Trial in Porto Alegre (Olaparib, Durvalumab)

      Terminated
      • Bladder Cancer
      • Urothelial Carcinoma
      • Porto Alegre, Brazil
        Centro de Pesquisa em Oncologia
      Jun 14, 2021

      Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle

      Recruiting
      • Muscle Invasive Bladder Carcinoma
      • +2 more
      • Lymphadenectomy
      • +2 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 9, 2023

      Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma,

      Active, not recruiting
      • Hydronephrosis
      • +18 more
      • Durvalumab
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 31, 2022

      Muscle Invasive Bladder Urothelial Carcinoma Trial in Saint Louis (Daily Adaptive External Beam Radiation Therapy)

      Not yet recruiting
      • Muscle Invasive Bladder Urothelial Carcinoma
      • Daily Adaptive External Beam Radiation Therapy
      • Saint Louis, Missouri
        Washington University, St. Louis
      Jan 17, 2023

      Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

      Recruiting
      • Muscle Invasive Bladder Carcinoma
      • +2 more
      • Indianapolis, Indiana
      • +1 more
      Jan 12, 2023